{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:39:51Z","timestamp":1791272391704,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jaad.2015.01.012","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T15:17:34Z","timestamp":1423322254000},"page":"786-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma"],"prefix":"10.1016","volume":"72","author":[{"given":"Marius","family":"Ilie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Long-Mira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lassalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Butori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lespinet-Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bordone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Zahaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Poissonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bahadoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ballotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Merlio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Vergier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Fran\u00e7ois","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.01.012_bib1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.012_bib2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjd.12504","article-title":"The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort","volume":"169","author":"Ekedahl","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.01.012_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molonc.2007.12.003","article-title":"Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site","volume":"1","author":"Platz","year":"2008","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jaad.2015.01.012_bib4","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2015.01.012_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/bjc.2014.287","article-title":"Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma","volume":"111","author":"Carlino","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2015.01.012_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.critrevonc.2014.05.005","article-title":"Nras in melanoma: targeting the undruggable target","volume":"92","author":"Mandala","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jaad.2015.01.012_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2015.01.012_bib8","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","article-title":"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma","volume":"31","author":"Trunzer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2015.01.012_bib9","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1073\/pnas.1216013110","article-title":"Combined targeting of MEK and PI3K\/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in\u00a0vitro and in\u00a0vivo","volume":"110","author":"Posch","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2015.01.012_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harboring NRAS or Val600 BRAF mutations: a non-randomized, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2015.01.012_bib11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/pcmr.12303","article-title":"Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma","volume":"27","author":"Rebecca","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaad.2015.01.012_bib12","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-13-3270","article-title":"Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia","volume":"20","author":"Johnson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2015.01.012_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1556-4029.2009.01245.x","article-title":"A study of PCR inhibition mechanisms using real time PCR","volume":"55","author":"Opel","year":"2010","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.jaad.2015.01.012_bib14","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1245\/s10434-012-2457-5","article-title":"Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes","volume":"19","author":"Moreau","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jaad.2015.01.012_bib15","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1089\/thy.2013.0302","article-title":"Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays","volume":"24","author":"Ilie","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.jaad.2015.01.012_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2 diagnostics in gastric cancer\u2013guideline validation and development of standardized immunohistochemical testing","volume":"457","author":"Ruschoff","year":"2010","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jaad.2015.01.012_bib17","doi-asserted-by":"crossref","unstructured":"Massi D, Simi L, Sensi E, et al. Immuhistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. Mod Pathol. doi: 10.1038\/modpathol.2014.137. Published online October 24, 2014.","DOI":"10.1038\/modpathol.2014.137"},{"key":"10.1016\/j.jaad.2015.01.012_bib18","unstructured":"Chiappetta C, Proietti I, Soccodato V, et al. BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. Appl Immunohistochem Mol Morphol. doi:\u00a010.1097\/PAI.0000000000000071. Published online April 5, 2014."},{"key":"10.1016\/j.jaad.2015.01.012_bib19","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation\u00a0frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2015.01.012_bib20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","article-title":"BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival","volume":"125","author":"Akslen","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2015.01.012_bib21","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2015.01.012_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","article-title":"Examination of mutations in BRAF, NRAS, and PTEN in primary\u00a0cutaneous melanoma","volume":"126","author":"Goel","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2015.01.012_bib23","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.humpath.2014.07.014","article-title":"Accurate detection of\u00a0BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays","volume":"45","author":"Fisher","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jaad.2015.01.012_bib24","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1007\/s13277-014-1759-6","article-title":"Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients","volume":"35","author":"Chen","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jaad.2015.01.012_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2407-14-13","article-title":"Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations","volume":"14","author":"Ihle","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaad.2015.01.012_bib26","doi-asserted-by":"crossref","first-page":"e70826","DOI":"10.1371\/journal.pone.0070826","article-title":"Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing","volume":"8","author":"Boursault","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2015.01.012_bib27","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1684\/bdc.2014.2041","article-title":"Immunohistochemistry and personalized medicine in lung oncology: advantages and limitations [in French]","volume":"101","author":"Hofman","year":"2014","journal-title":"Bull Cancer"},{"key":"10.1016\/j.jaad.2015.01.012_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.13032\/tjop.2052-5931.100013","article-title":"The potential value of immunohistochemistry as a screening tool for oncogenic targets of personalized lung cancer therapy","volume":"1","author":"Ilie","year":"2013","journal-title":"J Oncopathol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:33:21Z","timestamp":1759271601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0190962215000511"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.01.012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725347168.793519595","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}